Compare GE Aerospace (GE) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Medpace Holdings Inc — how do they compare? GE Aerospace trades at $306.87 (market cap $317.10B), while Medpace Holdings Inc trades at $618.69 (market cap $16.82B). The key difference: GE Aerospace is far larger — about 18.9× Medpace Holdings Inc's market cap, and GE Aerospace pays a 0.62% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Medpace Holdings Inc for 14 Days on average.
| GE | MEDP | |
|---|---|---|
Market Cap | $317.10B | $16.82B |
Volume | 6,320,106 | 223,093 |
Sector | Industrials | Health |
52-Week High | $381.22 | $630.19 |
52-Week Low | $273.25 | $393.42 |
Typical Hold Time | 111 Days | 14 Days |
Enterprise Value | $326.91B | $16.44B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $303.62, down 1.86% amid broader market weakness, with technical indicators showing bearish momentum despite strong fundamentals. The company has consistently beaten earnings expectations with Q2 2026 EPS of $2.02 exceeding estimates, while revenue growth accelerated to $45.86 billion in 2025. Recent news highlights GE's $12 billion acquisition of Consolidated Precision Products to address supply chain constraints in jet engine components.
The stock presents a compelling value opportunity with a 35% upside to the consensus price target of $409.60, supported by 24 buy ratings and no sell recommendations. However, high valuation multiples and integration risks from the CPP acquisition warrant caution. Strong free cash flow generation and shareholder returns through dividends and buybacks provide downside protection.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
